Pharmacokinetics of gatifloxacin in infants and children.
Gatifloxacin is an 8-methoxy fluoroquinolone effective against a broad spectrum of pathogens common in pediatric infections. The safety and pharmacokinetics of a single dose of gatifloxacin were studied in pediatric patients from 6 months to 16 years of age. Seventy-six pediatric patients (average age, 6.7 +/- 5.0 years) were administered a single oral dose of gatifloxacin suspension (5, 10, or 15 mg/kg of body weight; 600-mg maximum) in a dose-escalating manner. Subjects were stratified by age into 4 groups. An additional 12 children, greater than 6 years of age, received gatifloxacin as the tablet formulation at a dose of approximately 10 mg/kg. Gatifloxacin's apparent clearance and half-life were 5.5 +/- 2.1 ml/min/kg and 5.1 +/- 1.4 h. The maximum concentration of drug in plasma and area under the concentration-time curve (AUC) increased in a manner approximately proportional to the dose. At the 10-mg/kg dose, the bioavailability was similar between the suspension and tablet formulation. The apparent oral clearance of gatifloxacin, normalized for body weight, exhibited a small but statistically significant decrease with increasing age. In all subjects receiving gatifloxacin at 10 mg/kg, the AUC exceeded 20 microg . h/ml (estimated free AUC/MIC ratio of > or =34 for MIC of < or =0.5 microg/ml). These data suggest that gatifloxacin at a dose of 10 mg/kg every 24 h will achieve therapeutic concentrations in plasma in infants and children.
Capparelli
Edmund V
EV
Pediatric Pharmacology Research Unit, University of California, San Diego, California, USA. ecapparelli@ucsd.edu
Reed
Michael D
MD
Bradley
John S
JS
Kearns
Gregory L
GL
Jacobs
Richard F
RF
Damle
Bharat D
BD
Blumer
Jeffrey L
JL
Grasela
Dennis M
DM
D000293:Adolescent; D019540:Area Under Curve; D002648:Child; D002675:Child, Preschool; D024841:Fluoroquinolones / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D000077734:Gatifloxacin; D006801:Humans; D007223:Infant; D008826:Microbial Sensitivity Tests
D024841:Fluoroquinolones; D000077734:Gatifloxacin
J Antimicrob Chemother. 2000 Apr;45(4):437-46
10747819
J Clin Microbiol. 1999 Apr;37(4):897-901
10074498
Pharmacotherapy. 2000 Jun;20(6 Pt 2):59S-66S
10850522
Pharmacotherapy. 2000 Jun;20(6 Pt 2):67S-75S
10850523
Pharmacotherapy. 2001 Jan;21(1):35-59
11191737
Antimicrob Agents Chemother. 2001 Jul;45(7):2092-7
11408228
Antimicrob Agents Chemother. 2001 Oct;45(10):2793-7
11557471
Int J Antimicrob Agents. 2001 Dec;18(6):531-5
11738340
Antimicrob Agents Chemother. 2002 Jan;46(1):69-74
11751113
Diagn Microbiol Infect Dis. 2002 Jul;43(3):207-17
12106954
Antimicrob Agents Chemother. 1993 May;37(5):1073-81
8517694
J Antimicrob Chemother. 1994 Apr;33(4):685-706
8056688
Clin Infect Dis. 1997 Nov;25(5):1196-204
9402381
Pediatr Rev. 1998 Mar;19(3):78-84
9509854
Antimicrob Agents Chemother. 1998 Oct;42(10):2650-5
9756771
Chemotherapy. 1998 Sep;44 Suppl 1:10-4
9797417
Diagn Microbiol Infect Dis. 1998 Nov;32(3):247-52
9884844
J Clin Microbiol. 1999 Mar;37(3):798-800
9986858
Antimicrob Agents Chemother. 1999 Feb;43(2):385-9
9925540
Pharmacotherapy. 2000 Jun;20(6 Pt 2):49S-58S
10850521